References
- 1. Moudgal V, Sobel JD. Clostridium difficile colitis: a review. Hosp Pract (1995). 2012; 40(1): 139-48.
- 2. Furuya-Kanamori L, Stone JC, Clark J, McKenzie SJ, Yakob L et al. Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015; 36(2): 132-41.
- 3. Gao T, He B, Pan Y, Deng Q, Sun H et al. Association of Clostridium difficile infection in hospital mortality: A systematic review and meta-analysis. Am J Infect Control. 2015; 43(12): 1316-20.
- 4. Goodhand JR, Alazawi W, Rampton D. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 33(4): 428-41.
- 5. Bavishi C, DuPont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Alimen Pharmacol Ther 2011; 34: 1269-81.
- 6. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012; 107(7): 1011-9.
- 7. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012; 107: 1001-10.
- 8. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH еt al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011; 377(9759): 63-73.
- 9. Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother 2006; 40: 2155 - 63.
- 10. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013; 68(9): 1951-61.
- 11. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta- analysis of antibiotics and the risk of communityassociated Clostridium difficile infection. Antimicrob Agents Chemother. 2013; 57(5): 2326-32.
- 12. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004; 171: 33-8.
- 13. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med. 2008; 359(18): 1932-40.
- 14. Tang-Feldman Y, Mayo S, Silva J Jr et al. Molecular аnalysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea. J Clin Microbiology 2003; 41: 3413-4.
- 15. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15: 1554-80.
- 16. Arvand M, Hauri AM, Zaiss NH, Witte W, Bettge- Weller G. Epidemiology of severe Clostridium difficile infections in Hesse, Germany in 2008-2009. Dtsch Med Wochenschr 2010; 135(40): 1963-7.
- 17. Goodhand JR, Alazawi W, Rampton D. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33(4): 428-41.
- 18. Bajaj JS, O’Leary JG, Reddy KR, Wong F, Olson JC et al. Second infections inde-pendently increase mortality in hospitalized patients with cirrhosis: the North American сonsortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012; 56(6): 2328-35.
- 19. Di X, Bai N, Zhang X, Liu B, Ni W et al. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis. 2015; 19(4):339-49
- 20. Shafran DM, Shafran SD. Treating Clostridium difficile infection. CMAJ. 2014;186: 7.